Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy

摘要: Abstract Background Clinical trials in men with biochemically recurrent prostate cancer (BRPC) have been hampered by long survival times, making overall (OS) a difficult end point to reach. Intermediate points are needed order conduct such within more feasible time frame. Patients and methods This is retrospective analysis of 450 BRPC following prostatectomy treated at single institution between 1981 2010, which 140 developed subsequent metastases. Androgen deprivation therapy (ADT) was deferred until after the development Cox regression models were investigate factors influencing OS. Results Median metastasis-free (MFS) 10.2 years [95% confidence interval (CI) 7.6–14.0 years]; median OS metastasis 6.6 (95%CI 5.8–8.4 years). Multivariable regressions identified four independently prognostic variables for OS: MFS (HR 0.77; 95% CI 0.63–0.94), number metastases (≤3 versus ≥4; HR 0.50; 0.29–0.85), pain (absent present; 0.43; 0.25–0.72), bisphosphonate use (yes no; 0.60; 0.37–0.98). Conclusions emerged as an independent predictor ADT may be reasonable intermediate future clinical trials. observation requires prospective validation.